Biological disease-modifying antirheumatic drugs (bDMARDs) are highly effective agents for the treatment of inf lammatory arthritis; however, they also possess a potential risk for serious infection. Recently, with the rapid expansion of the bD-MARDs market in Korea, reports of serious adverse events related to the agents have also increased, necessitating guidance for the use of bDMARDs. Current work entitled, “Expert consensus for the use of bDMARDs drugs for inflammatory arthritis in Korea,” is the first to describe the appropriate use of bDMARDs in the management of inflammatory arthritis in Korea, with an aim to provide guidance for the local medical community to improve the quality of clinical care. Twelve consensus statements regarding the use of bDMARDs for the management of rheumatoid arthritis and ankylosing spondylitis were generated. In this review, we provide detailed guidance on bDMARDs use based on expert consensus, including who should prescribe, the role of education, indications for use, and monitoring strategies for safety.
Bibliographical noteFunding Information:
The Task Force gratefully acknowledges the contribution of the consensus group members for participating in the agreement process of the statements and for generously sharing their expert opinions. We would also like to acknowledge KCR Executive Committee for the endorsement of the Expert Consensus.
© Korean Association of Internal Medicine. All rights reserved.
- Biological disease-modifying antirheumatic drugs
- Expert consensus
- Inflammatory arthritis